EFFECT OF CURRENT MAGNITUDE AND DRUG CONCENTRATION ON IONTOPHORETIC DELIVERY OF OCTREOTIDE ACETATE (SANDOSTATIN(R)) IN THE RABBIT

被引:28
作者
LAU, DTW
SHARKEY, JW
PETRYK, L
MANCUSO, FA
YU, ZL
TSE, FLS
机构
[1] SANDOZ PHARMACEUT CORP,SANDOZ RES INST,TECH RES & DEV,PHARM RES GRP,E HANOVER,NJ 07936
[2] SANDOZ PHARMACEUT CORP,SANDOZ RES INST,DEPT DRUG METAB & PHARMACOKINET,E HANOVER,NJ 07936
关键词
IONTOPHORESIS; OCTREOTIDE; TRANSDERMAL; PEPTIDE; RABBIT;
D O I
10.1023/A:1018963300092
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The effect of current magnitude and drug concentration on transdermal iontophoretic delivery of octreotide acetate (Sandostatin(R)) was examined in the rabbit. Plasma samples were collected over 24 hours and octreotide concentrations were determined by a radioimmunoassay. Without an electrical current, negligible plasma concentrations of octreotide were obtained. Following initiation of iontophoresis, plasma concentrations of octreotide increased rapidly, although did not sustain at a plateau level during the dosing period. Octreotide concentrations declined rapidly after removal of the device. Increasing the electrical current from 50 mu A/cm(2) to 150 mu A/cm(2) yielded a proportional increase in the delivery. Increasing the drug concentration in the device from 2.5 mg/mL to 5 mg/mL resulted in approximately proportional increase in plasma octreotide concentrations; however, further increase in plasma concentrations was not observed for drug concentrations beyond 5 mg/mL. Iontophoretic delivery at the conditions which yielded the highest octreotide concentrations in this study (5 mg/mL solution at 150 mu A/cm(2) for 8 hours) yielded an apparent bioavailability (which represents an underestimate of the absolute bioavailability determined when the patches are run to exhaustion) of approximately 8%.
引用
收藏
页码:1742 / 1746
页数:5
相关论文
共 23 条
[1]  
BAUER W, 1982, LIFE SCI, V31, P1133, DOI 10.1016/0024-3205(82)90087-X
[2]   COMPARISON BETWEEN THE IONTOPHORETIC AND PASSIVE TRANSPORT OF THYROTROPIN-RELEASING-HORMONE ACROSS EXCISED NUDE-MOUSE SKIN [J].
BURNETTE, RR ;
MARRERO, D .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1986, 75 (08) :738-743
[3]  
Delgado-Charro Begona, 1992, Pharmaceutical Research (New York), V9, pS67
[4]   ENDOCRINE PROFILE OF A LONG-ACTING SOMATOSTATIN DERIVATIVE SMS-201-995 - STUDY IN NORMAL VOLUNTEERS FOLLOWING SUBCUTANEOUS ADMINISTRATION [J].
DELPOZO, E ;
NEUFELD, M ;
SCHLUTER, K ;
TORTOSA, F ;
CLARENBACH, P ;
BIEDER, E ;
WENDEL, L ;
NUESCH, E ;
MARBACH, P ;
CRAMER, H ;
KERP, L .
ACTA ENDOCRINOLOGICA, 1986, 111 (04) :433-439
[5]  
FRICKER G, 1992, BRIT J PHARMACOL, V105, P783
[6]  
Gibaldi M., 1982, PHARMACOKINETICS, P445
[7]  
HOOGSTRAATE AJ, 1991, P INT S CONTROLLED R, V18, P299
[8]   ABSORPTION OF AN AQUEOUS-SOLUTION OF A NEW SYNTHETIC SOMATOSTATIN ANALOG ADMINISTERED TO MAN BY GAVAGE [J].
KOHLER, E ;
DUBEROWDREWE, M ;
DREWE, J ;
RIBES, G ;
LOUBATIERESMARIANI, MM ;
MAZER, N ;
GYR, K ;
BEGLINGER, C .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 33 (02) :167-171
[9]   PHARMACOKINETICS OF SMS-201-995 IN HEALTHY-SUBJECTS [J].
KUTZ, K ;
NUESCH, E ;
ROSENTHALER, J .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1986, 21 :65-72
[10]   LONG-TERM TREATMENT OF ACROMEGALY WITH THE SOMATOSTATIN ANALOG SMS 201-995 [J].
LAMBERTS, SWJ ;
UITTERLINDEN, P ;
VERSCHOOR, L ;
VANDONGEN, KJ ;
DELPOZO, E .
NEW ENGLAND JOURNAL OF MEDICINE, 1985, 313 (25) :1576-1578